Genómica traslacional y terapias dirigidas en tumores sólidos
Publicaciones destacadas
-
Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer
Villacampa G; Tung NM; Pernas S; Paré L; Bueno-Muiño C;(...)Carey LA; Mittendorf EA; Martín M; Prat A; Tolaney SM.Referencia:Annals Of Oncology 2023.
-
Customizing local and systemic therapies for women with early breast cancer: the st. gallen international consensus guidelines for treatment of early breast cancer 2021
H J Burstein; G Curigliano; B Thürlimann; W P Weber; P Poortmans 5;M M Regan; H J Senn; E P Winer; M Gnant; Panelists of the St Gallen Consensus Conference.Referencia:Ann Oncol. 2021.
-
Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy
Pascual, T; Fernandez-Martinez, A; Tanioka, M; Dieci, MV; Pernas, S;(...)Pare, L; Galvan, P; Carey, LA; Perou, C; Prat, A.Referencia:Clinical Cancer Research 2021.
-
Correlative Biomarker Analysis of Intrinsic Subtypes
Prat Aparicio; Aleix;Referencia:2021.
-
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation
Prat A; Guarneri V; Paré L; Griguolo G; Pascual T;(...)Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P.Referencia:Lancet Oncology 2020.
-
Frequency and spectrum of PIK3CA somatic mutations in breast cancer
Martínez-Sáez O; Chic N; Pascual T; Adamo B; Vidal M;(...)Galván P; Rodríguez AB; Martinez A; Muñoz M; Prat A .Referencia:Breast Cancer Research 2020.
-
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
Brasó-Maristany F.; Griguolo G.; Pascual T.; Paré L.; Nuciforo P.;(...)Gomis R.R.; Villagrasa P.; Cortés J.; Ciruelos E.; Prat A..Referencia:Nature Communications 2020.
-
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial
Prat A; Saura C; Pascual T; Hernando C; Muñoz M;(...)López R; Céliz P; Ciruelos E; Villagrasa P; Gavilá J .Referencia:Lancet Oncology 2020.